Teacher Retirement System of Texas Takes $189,000 Position in Replimune Group, Inc. (NASDAQ:REPL)

Teacher Retirement System of Texas acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,603 shares of the company’s stock, valued at approximately $189,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new stake in shares of Replimune Group during the third quarter worth $133,000. Arizona State Retirement System acquired a new stake in Replimune Group in the 4th quarter worth about $156,000. BNP Paribas Financial Markets grew its holdings in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after buying an additional 6,748 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Replimune Group by 24.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after acquiring an additional 3,177 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Replimune Group during the 3rd quarter worth about $252,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REPL has been the topic of a number of recent analyst reports. BMO Capital Markets increased their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Price Performance

Shares of REPL stock opened at $8.62 on Thursday. The firm has a fifty day simple moving average of $12.51 and a 200-day simple moving average of $12.12. The company has a market capitalization of $663.87 million, a PE ratio of -2.81 and a beta of 1.30. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.